New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2014
04:55 EDTPRGO, PRGO, QSII, QSII, PKI, PKI, AMAG, AMAG, AMBI, AMBI, LLY, LLY, WAT, WAT, CSII, CSII, BLUE, BLUELeerink to hold a conference
2014 Global Healthcare Conference is being held in New York on February 12-13.
News For PRGO;QSII;PKI;AMAG;AMBI;LLY;WAT;CSII;BLUE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 28, 2015
08:08 EDTPRGOGalmed and Perrigo sign agreement for aramchol API production
Galmed (GLMD) has entered into a Manufacturing Services Agreement with Perrigo (PRGO) subsidiary Perrigo API Ltd. for the large-scale production of the active pharmaceutical ingredient of Galmed's product candidate, aramchol. The API produced pursuant to this agreement is expected to provide sufficient quantities of aramchol for Galmed's potential future Phase III clinical trials of aramchol for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH. The agreement also provides Perrigo with the option to manufacture commercial supplies of the aramchol API in the future.
January 26, 2015
17:26 EDTWATWaters sees Q1 EPS 95c-$1.05, consensus $1.07
Subscribe for More Information
17:25 EDTWATWaters sees FY15 EPS $5.55-$5.80, consensus $5.84
Sees stable increases in revenue during FY15. Sees FY15 market conditions better than in FY14. Guidance provided during Q4 earnings conference call.
16:02 EDTWATWaters reports Q4 EPS $1.99, consensus $1.89
Subscribe for More Information
10:00 EDTAMAGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:20 EDTAMAGAMAG Pharmaceuticals transferred with a Market Perform at FBR Capital
FBR Capital transferred coverage of AMAG Pharmaceuticals with a Market Perform rating, a downgrade from its previous rating of Outperform. FBR believes Feraheme growth will be limited to market share gains and that Makena expectations are fully realized at current valuation levels. The firm has a $42 price target for AMAG shares.
January 23, 2015
12:18 EDTQSIIQuality Systems management to meet with Topeka
Subscribe for More Information
January 22, 2015
12:20 EDTQSIIQuality Systems upgraded earlier to Hold from Sell at Evercore ISI
Subscribe for More Information
07:43 EDTBLUEbluebird bio reinstated with a Buy at BofA/Merrill
Subscribe for More Information
05:34 EDTQSIIQuality Systems reports Q3 non-GAAP EPS 16c, consensus 14c
Subscribe for More Information
January 21, 2015
12:27 EDTBLUEbluebird bio price target raised to $146 from $94 at Wedbush
Subscribe for More Information
10:16 EDTLLYLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
January 20, 2015
13:21 EDTBLUECAR T-Cell therapy drug stocks down sharply following NY Times story
Shares of biotechnology companies that are developing chimeric antigen receptor T cells or CAR T therapy drugs are falling sharply after a New York Times story titled "Riding High, Biotech Firms Remain Wary." WHAT'S NEW: Over the weekend, the New York Times published the story that struck a cautionary tone on the CAR-T therapy drugs. In this form of cancer treatment the patients own immune system cells are genetically manipulated to battle tumors. The New York Times story noted that there were some notable outcomes in the treatment of leukemia and lymphoma with the CAR T treatments but highlighted that the "technique is still early in development and can cause severe side effects." WHAT'S NOTABLE. Early last week, Intrexon (XON) and its oncology partner, ZIOPHARM Oncology (ZIOP), announced an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sub-licensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies. Both companies' shares were up sharply following the announcement ZIOPHARM was up around 55% and Intrexon up over 30% the day following the announcement. PRICE ACTION: Shares of drug companies in the space are sharply lower in midday trading, with ZIOPHARM Oncology and Kite Pharma (KITE) each down over 9%, Intrexon down almost 12%, and Bellicum Pharmaceutical (BLCM) and bluebird bio (BLUE) each down almost 5%. Reference Link
11:16 EDTPRGOPerrigo management to meet with B. Riley
Subscribe for More Information
January 15, 2015
11:20 EDTLLYGoldman cuts J&J to sell citing competitive pressures
Subscribe for More Information
10:00 EDTLLYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:07 EDTLLYEli Lilly upgraded at Goldman
As previously reported, Goldman upgraded Eli Lilly to Neutral from Sell. The firm upgraded shares based on new product launches and pipeline assets, and cost reductions. Price target is $70.
06:44 EDTLLYEli Lilly upgraded to Neutral from Sell at Goldman
Subscribe for More Information
January 14, 2015
07:37 EDTAMAGJPMorgan to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use